NEW YORK (GenomeWeb) – IBM Watson Health announced today that it has signed an agreement making Baheal Pharmaceutical Group the primary channel partner for its Watson for Genomics platform in China.

Watson for Genomics is designed to analyze large sets of genomic, clinical, and pharmacological data to generate a report for physicians that identifies genetic alterations that are actionable based on literature, as well as drugs and clinical trials that target those alterations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.